HGH Fragment 176-191: Lipolytic GH Fragment Research, Fat Metabolism & AOD-9604

Written by NorthPeptide Research Team

For laboratory and research use only. Not for human consumption.

What Is HGH Fragment 176-191?

HGH Fragment 176-191, commonly referred to as HGH Frag, is a synthetic peptide corresponding to amino acids 176 through 191 of the C-terminal region of human growth hormone (hGH). This 16-amino-acid fragment represents the specific portion of the growth hormone molecule that researchers have identified as responsible for growth hormone’s lipolytic (fat-metabolizing) activity.

Human growth hormone is a 191-amino-acid protein secreted by the anterior pituitary gland. While full-length hGH exerts a wide range of physiological effects — including growth promotion, IGF-1 elevation, glucose metabolism alterations, and lipid mobilization — research conducted from the late 1980s onward demonstrated that the fat-metabolizing activity of hGH could be isolated to a specific structural region. The C-terminal fragment spanning residues 176-191 was identified as the minimal sequence necessary to reproduce the lipolytic effects observed with full-length growth hormone in preclinical models.

What makes HGH Fragment 176-191 particularly notable in research is what it does not appear to do. Unlike full-length growth hormone, this fragment has not been observed to significantly elevate insulin-like growth factor 1 (IGF-1) levels, promote skeletal growth, or exert the diabetogenic effects (impaired glucose tolerance and insulin resistance) associated with chronic growth hormone administration. This separation of lipolytic activity from the broader hormonal effects of hGH has made it a subject of considerable interest in fat metabolism and obesity research.

HGH Fragment 176-191 is also recognized as the precursor to AOD-9604, a closely related peptide that adds a tyrosine residue to the C-terminus of the fragment for improved stability. The relationship between these two compounds — and how they differ — is explored in detail later in this guide.

Mechanism of Action: Lipolysis Without Growth Promotion

The mechanism through which HGH Fragment 176-191 influences fat metabolism has been investigated in multiple preclinical studies. The key finding across this body of research is that the fragment reproduces the lipolytic signaling of full-length growth hormone through a pathway that is distinct from the growth-promoting and metabolic pathways mediated by the GH receptor’s intracellular domain.

Stimulation of Lipolysis

Lipolysis is the biochemical process by which stored triglycerides in adipose tissue are hydrolyzed into free fatty acids and glycerol, which can then be utilized as energy substrates. Full-length growth hormone is a well-established lipolytic agent, and research has demonstrated that the 176-191 region is sufficient to activate this process. In adipose tissue models, HGH Fragment 176-191 has been observed to stimulate the activity of hormone-sensitive lipase (HSL), the enzyme primarily responsible for triglyceride hydrolysis in fat cells. This stimulation appears to occur through a beta-adrenergic-like signaling pathway involving cyclic AMP (cAMP) elevation, though the precise upstream receptor interactions remain an area of active investigation.

Inhibition of Lipogenesis

Beyond promoting fat breakdown, HGH Fragment 176-191 has been observed to inhibit lipogenesis — the metabolic process by which new fatty acids are synthesized and stored as triglycerides. In preclinical models, the fragment has demonstrated an ability to suppress the activity of key lipogenic enzymes, including fatty acid synthase and acetyl-CoA carboxylase, in adipose tissue. This dual action — stimulating fat breakdown while simultaneously inhibiting fat formation — represents a mechanism distinct from most other lipolytic agents, which typically affect only one side of the fat metabolism equation.

Absence of IGF-1 Elevation

One of the most significant research findings regarding HGH Fragment 176-191 is its lack of effect on circulating IGF-1 levels. Full-length growth hormone exerts many of its anabolic and growth-promoting effects through the GH-IGF-1 axis: GH binds its receptor in the liver and other tissues, triggering the production and release of IGF-1, which then mediates downstream growth effects. Research has consistently shown that HGH Fragment 176-191 does not activate this axis to a physiologically significant degree. This observation has been reproduced across multiple animal studies and is considered one of the fragment’s defining pharmacological characteristics.

No Diabetogenic Effects Observed

Chronic administration of full-length growth hormone is associated with insulin resistance and impaired glucose tolerance — effects collectively described as diabetogenic. These metabolic consequences are mediated through GH’s direct effects on insulin signaling pathways and are a significant limitation in growth hormone research. HGH Fragment 176-191, by contrast, has not demonstrated diabetogenic activity in the preclinical models where it has been studied. Blood glucose levels and insulin sensitivity parameters have remained largely unaffected by fragment administration in animal studies, further distinguishing its pharmacological profile from that of full-length growth hormone.

Selective Activity on Adipose Tissue

The selectivity of HGH Fragment 176-191 for adipose tissue — without accompanying effects on muscle, bone, or organ growth — has been characterized as a form of “functional dissection” of growth hormone’s activity. By isolating the lipolytic domain from the growth-promoting and metabolic domains of the full-length molecule, researchers have created a tool for studying fat metabolism independently of the confounding variables introduced by whole-GH administration. This selectivity is the primary reason the fragment has attracted interest in obesity and body composition research.

Key Research Areas and Preclinical Evidence

Fat Metabolism and Obesity Studies

The most extensively studied application of HGH Fragment 176-191 is in fat metabolism and obesity models. Research in obese rodent models has demonstrated that chronic administration of the fragment resulted in significant reductions in body fat mass without corresponding changes in lean body mass, food intake, or blood glucose levels. These findings were first reported by Ng and Borstein in studies conducted at Monash University in Australia, where much of the foundational research on this fragment was performed.

In diet-induced obesity models, HGH Fragment 176-191 administration was associated with reduced adipocyte (fat cell) size and decreased expression of lipogenic gene markers in white adipose tissue. Visceral fat depots — the metabolically active fat stores associated with metabolic dysfunction in research models — appeared to be particularly responsive to fragment treatment, though the mechanisms underlying this depot-specific effect have not been fully elucidated.

Body Composition Research

Beyond simple fat mass reduction, several studies have examined HGH Fragment 176-191’s effects on overall body composition. In ob/ob mouse models (a genetic model of severe obesity), the fragment produced measurable reductions in total body weight and fat mass over treatment periods ranging from two to four weeks. Importantly, lean body mass was preserved in these studies, suggesting that the fragment’s catabolic effects are specific to adipose tissue rather than representing a generalized wasting effect.

Adipocyte Differentiation Studies

In vitro research using preadipocyte cell lines has examined HGH Fragment 176-191’s effects on fat cell differentiation — the process by which precursor cells mature into functional adipocytes. Some studies have observed that the fragment inhibits the terminal differentiation of preadipocytes, potentially reducing the capacity for new fat cell formation. This finding, if confirmed in more complex models, would represent an additional mechanism beyond the fragment’s acute lipolytic and anti-lipogenic effects.

Cartilage and Joint Research

An unexpected finding in HGH Fragment 176-191 research has been observations related to cartilage metabolism. While not the primary focus of investigation, some studies — particularly those conducted in the context of AOD-9604 research — have noted effects on chondrocyte (cartilage cell) activity. These observations have been more thoroughly investigated with AOD-9604 (discussed below) but suggest that the 176-191 region of growth hormone may interact with cartilage tissue in ways that extend beyond simple fat metabolism.

HGH Fragment 176-191 vs. AOD-9604: Understanding the Relationship

The relationship between HGH Fragment 176-191 and AOD-9604 is frequently a source of confusion, and understanding the distinction is important for researchers working with either compound.

Structural Relationship

AOD-9604 (Anti-Obesity Drug 9604) is a modified version of HGH Fragment 176-191. Specifically, AOD-9604 consists of the same amino acid sequence — residues 176-191 of human growth hormone — with the addition of a single tyrosine (Tyr) residue at the C-terminus. This modification was introduced by researchers at Monash University to improve the peptide’s stability and bioavailability. The two compounds share the same active region and the same fundamental mechanism of action; AOD-9604 is, in essence, HGH Fragment 176-191 with a stability-enhancing modification.

Differences in Research History

While both compounds derive from the same research lineage, their development trajectories have diverged significantly. AOD-9604 progressed further through formal clinical development, including human clinical trials for obesity. A Phase IIb clinical trial evaluated oral AOD-9604 in overweight and obese adults, though the results were ultimately deemed insufficient for regulatory approval. AOD-9604 also received Generally Recognized as Safe (GRAS) status from the FDA in 2014 for use as a food ingredient, a designation that HGH Fragment 176-191 has not received.

HGH Fragment 176-191, lacking the stability modification, has a less extensive clinical development history but continues to be widely used in preclinical research. Its simpler structure — identical to the native GH sequence without modification — makes it a useful reference compound for studying the endogenous lipolytic activity of the growth hormone C-terminal region.

Practical Differences for Researchers

From a research perspective, the key practical differences between the two compounds relate to stability and half-life. AOD-9604’s C-terminal tyrosine modification confers greater resistance to enzymatic degradation, potentially resulting in a longer effective half-life in biological systems. HGH Fragment 176-191, being an unmodified native sequence, may be more susceptible to proteolytic degradation but more closely represents the endogenous lipolytic signal of growth hormone. The choice between the two compounds for a given research application depends on whether the investigator prioritizes physiological fidelity (favoring the unmodified fragment) or practical stability (favoring AOD-9604).

For researchers interested in AOD-9604 specifically, NorthPeptide provides a dedicated research guide covering its clinical trial history and regulatory status. AOD-9604 is available as a separate product.

Reconstitution and Handling for Research Use

HGH Fragment 176-191 is supplied as a lyophilized (freeze-dried) powder and must be reconstituted before use in research protocols. Proper handling is essential for maintaining peptide integrity and ensuring reproducible experimental results.

Reconstitution Protocol

The standard reconstitution vehicle for HGH Fragment 176-191 is bacteriostatic water (sterile water containing 0.9% benzyl alcohol as a preservative). To reconstitute, inject the bacteriostatic water slowly along the inside wall of the vial, allowing it to flow down to the lyophilized powder. Do not shake or agitate the vial vigorously, as this can damage the peptide through mechanical stress and surface adsorption. Instead, gently swirl the vial until the powder is fully dissolved, producing a clear solution.

Storage Conditions

Lyophilized (unreconstituted) HGH Fragment 176-191 should be stored at -20 degrees Celsius for long-term stability. Once reconstituted, the solution should be stored at 2-8 degrees Celsius (standard refrigeration) and used within a reasonable timeframe to ensure peptide integrity. Avoid repeated freeze-thaw cycles, as these can promote aggregation and degradation. For studies requiring aliquoting, divide the reconstituted solution into single-use volumes promptly after reconstitution.

Purity and Quality Considerations

Research-grade HGH Fragment 176-191 should meet a minimum purity standard of 98% or higher, as verified by high-performance liquid chromatography (HPLC) and mass spectrometry. Researchers should request certificates of analysis (COA) from their supplier and verify that the molecular weight and amino acid sequence match the expected specifications. Contamination with other peptide fragments or synthesis byproducts can introduce confounding variables into experimental results.

Limitations of Current Research

As with any peptide compound in the preclinical research phase, an honest assessment of HGH Fragment 176-191’s evidence base requires acknowledgment of significant limitations.

Predominantly Animal Model Data

The vast majority of research on HGH Fragment 176-191 has been conducted in rodent models, primarily mice and rats. While these models provide valuable mechanistic insights, the translation of preclinical findings to human physiology is not guaranteed. Differences in adipose tissue biology, growth hormone receptor expression patterns, and metabolic regulation between rodents and humans mean that effects observed in animal studies may not be reproduced at equivalent magnitudes — or at all — in human systems.

Limited Human Clinical Data

Unlike its derivative AOD-9604, which underwent Phase II clinical trials, HGH Fragment 176-191 in its unmodified form has not been evaluated in formal human clinical trials. The human data that does exist for this specific sequence comes primarily from AOD-9604 studies, which test the modified rather than native fragment. Researchers should be cautious about extrapolating AOD-9604 clinical findings directly to HGH Fragment 176-191, as the C-terminal tyrosine modification may influence pharmacokinetics, bioavailability, and tissue distribution.

Mechanism Not Fully Characterized

While the lipolytic and anti-lipogenic effects of HGH Fragment 176-191 have been documented across multiple studies, the precise receptor-level interactions that mediate these effects remain incompletely understood. The fragment does not appear to signal through the classical growth hormone receptor in the same manner as full-length GH, yet it clearly interacts with adipose tissue through some receptor-mediated mechanism. Identifying this receptor or signaling complex would represent a significant advance in understanding the fragment’s pharmacology.

Long-Term Safety Data Absent

No long-term safety studies have been conducted with HGH Fragment 176-191 in any species. While acute and short-term studies in rodents have not reported significant adverse effects, the consequences of chronic administration — particularly regarding adipose tissue homeostasis, endocrine function, and metabolic regulation over extended periods — remain unknown.

Dosing Protocols Not Standardized

Preclinical studies have employed varying doses, routes of administration, and treatment durations, making direct comparisons across studies difficult. No consensus exists regarding optimal research dosing protocols, and the allometric scaling factors required to translate rodent doses to potential human-equivalent doses have not been validated for this specific compound.

Related Research Compounds

Researchers investigating HGH Fragment 176-191 may also find the following compounds relevant to their work, as they represent related areas of peptide research in growth hormone biology and body composition:

• AOD-9604 — The tyrosine-modified derivative of HGH Fragment 176-191 with a more extensive clinical development history, including human trials and GRAS designation. Shares the same core mechanism of lipolysis stimulation and lipogenesis inhibition.
• Ipamorelin — A selective growth hormone secretagogue that stimulates endogenous GH release through the ghrelin receptor. Unlike HGH Fragment 176-191, ipamorelin promotes full-spectrum growth hormone activity including IGF-1 elevation, representing a complementary rather than overlapping research tool.
• CJC-1295 — A growth hormone-releasing hormone (GHRH) analog that extends the half-life of GHRH signaling. Often studied in combination with ipamorelin for synergistic GH release. Like ipamorelin, CJC-1295 promotes full GH axis activation rather than isolated lipolytic activity.

Frequently Asked Questions

What is HGH Fragment 176-191?

HGH Fragment 176-191 is a synthetic peptide consisting of amino acids 176 through 191 from the C-terminal end of human growth hormone. This specific region has been identified in preclinical research as the portion of GH responsible for its lipolytic (fat-metabolizing) activity. The fragment reproduces the fat metabolism effects of growth hormone without the growth-promoting, IGF-1-elevating, or diabetogenic effects of the full-length molecule.

How does HGH Fragment 176-191 differ from full-length growth hormone?

Full-length human growth hormone is a 191-amino-acid protein that activates multiple biological pathways, including growth promotion, IGF-1 production, glucose metabolism alteration, and lipolysis. HGH Fragment 176-191 isolates only the lipolytic activity. In preclinical models, it does not significantly elevate IGF-1, does not promote skeletal or organ growth, and does not impair glucose tolerance — effects that are characteristic of full-length GH administration.

What is the relationship between HGH Fragment 176-191 and AOD-9604?

AOD-9604 is HGH Fragment 176-191 with a single tyrosine amino acid added at the C-terminus. This modification was introduced to improve peptide stability and bioavailability. Both compounds share the same active region and fundamental mechanism of action. AOD-9604 has a more extensive clinical development history, including human trials and FDA GRAS designation, while HGH Fragment 176-191 more closely represents the native GH sequence.

Does HGH Fragment 176-191 raise IGF-1 levels?

In the preclinical studies conducted to date, HGH Fragment 176-191 has not been observed to significantly elevate circulating IGF-1 levels. This is one of the peptide’s defining characteristics and distinguishes it from full-length growth hormone, which potently stimulates IGF-1 production through the GH-IGF-1 axis.

How is HGH Fragment 176-191 reconstituted for research?

The lyophilized peptide is reconstituted with bacteriostatic water. The water should be added slowly along the vial wall and the vial gently swirled — not shaken — until the powder dissolves completely. Once reconstituted, the solution should be refrigerated at 2-8 degrees Celsius and used within an appropriate timeframe. Avoid repeated freeze-thaw cycles.

Has HGH Fragment 176-191 been tested in human clinical trials?

HGH Fragment 176-191 in its unmodified form has not been evaluated in formal human clinical trials. Its derivative AOD-9604 did undergo Phase II clinical trials for obesity, but the unmodified fragment’s human evidence is limited to data extrapolated from the AOD-9604 program. Researchers should note that the structural modification in AOD-9604 may influence pharmacokinetic properties compared to the native fragment.

What research models have been used to study HGH Fragment 176-191?

The majority of research has been conducted in rodent models, including diet-induced obesity models, ob/ob mice (genetic obesity), and normal-weight animal models. Study designs have employed subcutaneous injection as the primary route of administration, with treatment durations ranging from days to several weeks. In vitro studies have also been performed using adipocyte and preadipocyte cell lines.

---

Summary of Key Research Areas

Research Area	Key Finding	Evidence Level
Lipolysis stimulation	Fragment activates hormone-sensitive lipase and promotes fat breakdown in adipose tissue	Preclinical (rodent, in vitro)
Lipogenesis inhibition	Suppression of lipogenic enzyme activity and new fat synthesis	Preclinical (rodent, in vitro)
IGF-1 independence	No significant elevation of circulating IGF-1 levels	Preclinical (rodent)
Glucose metabolism	No diabetogenic effects observed; glucose tolerance unimpaired	Preclinical (rodent)
Body composition	Selective reduction of fat mass with preservation of lean mass	Preclinical (rodent)
AOD-9604 clinical trials	Phase IIb trial in obese adults (modified fragment); insufficient for approval	Human (AOD-9604 only)
Cartilage effects	Preliminary observations of chondrocyte activity modulation	Preclinical (limited)

---

---

Summary of Key Research References

Study	Year	Type	Focus	Reference
Habibullah et al.	2022	Original Research	HGH Fragment 176-191 enhances doxorubicin-loaded nanoparticle toxicity against cancer cells	PMC9249349
Misra et al.	2013	Review	Obesity pharmacotherapy including GH fragment-based approaches	PMC3584306
Heffernan et al.	2001	Original Research	Effects of human GH and lipolytic fragment AOD9604 on lipid metabolism in obese mice	PubMed 11713213
Ng et al.	2000	Original Research	Oral AOD9604 effects on lipid metabolism in obese Zucker rats	PubMed 10950816
Heffernan et al.	2001	Original Research	Chronic GH fragment treatment increases fat oxidation and weight loss in obese mice	PubMed 11673763
Ng et al.	2000	Original Research	Metabolic studies of synthetic lipolytic domain AOD9604 of human growth hormone	PubMed 11146367
Ng et al.	1993	Original Research	Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone	PubMed 8358331

Research Disclaimer

For laboratory and research use only. Not for human consumption.

This article is intended solely as a summary of published scientific research on HGH Fragment 176-191. It does not constitute medical advice, treatment recommendations, or an endorsement of HGH Fragment 176-191 for any therapeutic purpose. HGH Fragment 176-191 has not been approved by the FDA or any regulatory agency for human use. The research discussed herein is predominantly preclinical (animal and cell culture studies), and results from such studies may not translate to human outcomes. Researchers should consult relevant institutional review boards and regulatory guidelines before designing studies involving this compound.

NorthPeptide supplies research-grade peptides for legitimate scientific investigation. All products are sold strictly for laboratory and research purposes. HGH Fragment 176-191